← All trials

NCT05461209

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Oct 20, 2022
Primary completion
Nov 15, 2022
Completion date
Nov 15, 2022
First posted
Jul 18, 2022
Last posted
Dec 20, 2022
Enrollment
0
Arms / groups
2 / —
Source
AACT · ctgov ingestion

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.